The TIM Company rebrands as InnoGI Technologies and introduces the SurroGut Platform to reshape industry norms and to support FDA Modernization Act 2.0

We are in the process of a gradual rebranding, starting with the transition to InnoGI Technologies as our new name. Our rebranding is key in reinforcing our commitment to advancing innovative technologies and solutions for GI research and oral drug delivery, addressing industry challenges with determination. Rest assured, our services will remain unchanged, along with our contact details, VAT number, and chamber of commerce information. Please click here to review our announcement and visit our website frequently to stay updated on our latest developments.


Please visit our website frequently to stay updated on our latest developments.


The TIM technology was introduced 30 years ago and has been further developed, currently representing the most advanced dynamic in vitro GI model available.

By employing a proprietary in vitro technology called TIM, TIM Studies have changed what’s possible with accurate predictions of the bioaccessibility of oral drug or food candidates.

“Multiple candidate formulations can be tested in a relative short period of time at a fraction of the cost of a clinical study”  – Pfizer

Scientists now have alternatives to relying solely on animal studies or traditional dynamic dissolution methods, which typically show moderate in vitro-in vivo correlations of around ~.5

TIM Studies exceed in predicting in vivo behaviour of novel formulations and drug products during transit in the gastrointestinal tract, with ~.9 In vitro-in vivo correlations.


TIM accurately explains the fate of the oral drug while travelling through the GI tract.

Our studies determine the fraction available for absorption (bioaccessible), luminal concentrations and the non-bioaccessible fraction.

The mechanics that make this possible include exact mimicking of the physiological transit times between GI segments, motility, pressure and shear forces, secretions, temperature control and local pH values.

TIM data can be combined with intestinal tissue explants or in silico models (i.e. Gastro+,Simcyp) for further drug performance assessment and blood plasma levels.